Skip to main content

Table 1 Baseline characteristic of 686 patients receiving NVP-based HAART.

From: Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study

Baseline characteristics

Not receiving fluconazole

Receiving fluconazole

Pvalue

 

(n = 225)

400 mg/week (n = 392)

200 mg/day (n = 69)

 

Gender: Male

116 (51.6%)

213 (54.3%)

49 (71.0%)

0.016

Female

109 (48.4%)

179 (45.7%)

20 (29.0%)

 

Age, years, mean ± SD

36.0 ± 7.5

35.0 ± 7.4

34.7 ± 8.03

0.200

Weight, kg., mean ± SD

54.9 ± 10.6

52.3 ± 10.0

51.4 ± 8.7

0.008

Previous opportunistic infections, patients (%)

    

Any major opportunistic infections

53 (23.6%)

120 (30.6%)

24 (34.8%)

0.368

Tuberculosis

32 (14.2%)

64 (16.3%)

17 (24.6%)

0.124

PCP

31 (13.8%)

47 (12.0%)

8 (11.6%)

0.787

Histoplasmosis

3 (1.3%)

1 (0.3%)

-

0.190

Penicilliosis

3 (1.3%)

0 (0.0%)

-

0.046

Toxoplasmosis

-

5 (1.3%)

-

0.151

MAC

2 (0.9%)

2 (0.5%)

-

0.669

Concurrent medication

    

Cotrimoxazole

176 (78.2%)

363 (93.3%)

57 (82.6%)

< 0.001

Antituberculous drugs

47 (20.9%)

82 (20.9%)

22 (31.9%)

0.095

Baseline CD4 cell count, cell/mm3, median (IQR)

85 (21–159)

18 (7–48)

16 (5–35)

< 0.001

Baseline % CD4, median (IQR)

7 (2–11)

2 (1–5)

2 (1–5)

< 0.001

Baseline plasma HIV RNA,

207,500

270,000

169,000

0.095

copies/ml, median (IQR)

(68,375–549,500)

(118,000–545,000)

(76,750–415,000)

 

Baseline AST, U/L, median (IQR)

31 (23–46.5)

32 (25–53.2)

34 (24–53)

0.358

Baseline ALT, U/L, median (IQR)

23 (17–39)

28 (17–45)

32 (17–49.5)

0.177

Baseline TB, mg/dl, median (IQR)

0.5 (0.4–0.65)

0.5 (0.4–0.7)

0.5 (0.4–0.8)

0.843